Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say

Published 29/09/2022, 19:36
Updated 29/09/2022, 20:10
© Reuters.  Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say

  • On Wednesday, Immunovant Inc (NASDAQ: NASDAQ:IMVT) announced a new anti-FcRn, IMVT-1402, at Roivant Sciences Ltd's (NASDAQ: ROIV) Investor Day.
  • IMVT-1402 is a new anti-FcRn monoclonal antibody that matches batoclimab's IgG lowering without affecting albumin and LDL.
  • HC Wainwright says the addition of IMVT-1402 broadens the anti-FcRn franchise.
  • The analyst maintains a Buy rating with a price target of $16.
  • Roivant is leveraging data and learnings from batoclimab studies to accelerate IMVT-1402's development and, contingent on IND approval plans to start a Phase 1 study in early 2023.
  • The analyst thinks the new product should allow Immunovant to compete more effectively with Argenx SE (NASDAQ: ARGX), considering efgartigimod's clean profile.
  • Additionally, IMVT-1402's profile advantageously positions Immunovant relative to Johnson & Johnson's (NYSE: JNJ (NYSE:JNJ)) development of nipocalimab.
  • Overall, SVB Leerink expects investors to approach ‘1402 value conservatively, pending the generation of human data and clinical de-risking.
  • The analyst is encouraged by IMVT's initiatives to diversify its pipeline beyond batoclimab and see the potential for long-term flexibility and strategic value.
  • The analyst reiterates the Outperform rating.
  • Price Action: IMVT shares are up 19% at $5.70 on the last check Thursday.
Dec 2021 Wells Fargo (NYSE:WFC)Initiates Coverage OnEqual-Weight
Nov 2021HC Wainwright & Co.MaintainsBuy
Aug 2021BairdDowngradesOutperformNeutral

View the Latest Analyst Ratings

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.